Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average PT from Analysts

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has earned a consensus rating of “Buy” from the five research firms that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $31.00.

Several research firms have recently weighed in on MPLT. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a research note on Friday. They issued a “buy” rating and a $28.00 price objective on the stock. Leerink Partnrs raised shares of Maplight Therapeutics to a “strong-buy” rating in a research note on Friday. Jefferies Financial Group assumed coverage on shares of Maplight Therapeutics in a research report on Friday. They set a “buy” rating and a $32.00 price objective on the stock. Wall Street Zen downgraded Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Morgan Stanley initiated coverage on shares of Maplight Therapeutics in a research report on Friday. They issued an “overweight” rating and a $34.00 price target on the stock.

Maplight Therapeutics Price Performance

Shares of NASDAQ:MPLT opened at $13.00 on Friday. Maplight Therapeutics has a one year low of $12.92 and a one year high of $20.86.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.